Lenvatinib is a small-molecule tyrosine kinase inhibitor that inhibits vascular endothelial
growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet …

Introduction Lenvatinib is an oral multitargeted tyrosine kinase inhibitor that has shown
efficacy and manageable safety across multiple cancer types. The recommended starting …

Background Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2,
and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor …

Aim: To investigate the safety and efficacy of lenvatinib in advanced thyroid cancer.
Patients/methods: In this Phase II study, 51 Japanese patients with radioiodine-refractory …

Background: The objectives of this phase I study were to assess the safety and tolerability of
E7080 in patients with advanced, refractory solid tumours; to determine the maximum …

Lenvatinib significantly prolonged progression‐free survival (PFS) versus placebo in
patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC) in the phase 3 …

Although kinase inhibitors (KI) frequently portray large interpatient variability, a 'one size fits
all'regimen is still often used. In the meantime, relationships between exposure-response …

Purpose: E7080, an oral multitargeted receptor tyrosine kinase inhibitor, has antiangiogenic
and antitumor activity. This Phase I study investigated maximum tolerated dose (MTD), dose …

The huge increase in type 2 diabetes is a burden worldwide. Many marketed compounds do
not address relevant aspects of the disease; they may already compensate for defects in …

In oncology trials, overall survival (OS) is considered the most reliable and preferred
endpoint to evaluate the benefit of drug treatment. Other relevant variables are also …